Topic Paragraphs
Call-To-Action Title
Virtual Press Conference - 6/17/2022 at 10:30 AM
Call-To-Action Title
Virtual Press Conference - 6/17/2022 at 10:30 AM
Join us for a virtual press conference to discuss the FDA’s emergency use authorization of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to six months of age. FDA Commissioner Dr. Robert M. Califf and FDA's Center for Biologics Evaluation and Research Director Dr. Peter Marks will be taking questions.
Join the Virtual Press Conference
Featured Topics
LGBTQI+ Health & Well-being
Join us in advancing equality for LGBTQI+ children and families and preventing discrimination against LGBTQI+ people.
Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.
New Era of Smarter Food Safety
A new approach to food safety that recognizes and builds on the progress made in the past but looks towards what processes and tools will be needed for the future.
Recent Press Announcements
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Jun 17
Freshpet Voluntarily Recalls One Lot of Freshpet Select Fresh from the Kitchen Home Cooked Chicken Recipe 4.5-Pound Bags Due to Potential Salmonella Contamination
Food & Beverages
Jun 15
888 Food Company Issues Allergy Alert On Undeclared Egg In Various Ho King and Giai Phat Products
Food & Beverages
Jun 10
Latin Foods Market Issues Voluntary Nationwide Recall of Artri King Reforzado Con Ortiga Y Omega 3 Due to the Presence of Undeclared Diclofenac and Dexamethasone
Drugs
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
FDA’s Center for Devices and Radiological Health’s Continued Efforts to Return to Normal: Reopening for All Pre-Submissions
We continue interactions with device submission sponsors as we work to return to normal operations while continuing to respond to the public health emergency.
FDA's “All-in” Approach to Enterprise Transformation
The Enterprise Modernization Action Plan is the next phase of FDA’s data and technology transformation and describes our plans to shape the agency’s future.
FDA Seeks to Engage Stakeholders on Key Considerations for a Drug Quality Management Maturity Program
Program Aims to Improve Drug Supply Chain, Mitigate Shortages
Recently Published Guidances
Jun 21
Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures
Medical Devices
Jun 16
Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions
Medical Devices, Radiation-Emitting Products
Jun 15
Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies
Biologics